Publication date: Available online 2 August 2017
Source:Seminars in Oncology
Author(s): Ralph Chebib, Loic Verlingue, Nathalie Cozic, Matthieu Faron, Pascal Burtin, Valérie Boige, Antoine Hollebecque, David Malka
The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.
http://ift.tt/2w7eTG0
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Ετικέτες
Τετάρτη 2 Αυγούστου 2017
Angiogenesis Inhibition in the Second-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου